



an Open Access Journal by MDPI

Molecular Research on Rare Thoracic Tumors

Guest Editors:

Dr. Giovannella Palmieri

Rare Tumors Coordinating Center of Campania Region (CRCTR), Universita degli Studi di Napoli Federico II, Naples, Italy

Dr. Mirella Marino

Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Deadline for manuscript submissions: closed (31 January 2023)

Message from the Guest Editors

Rare thoracic tumors include epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, mesothelioma of pleura and pericardium, mediastinal germ cell tumors, neuroendocrine tumors of the thymus and lung, lymphoma of the mediastinum, and sarcoma of the thoracic cavity. These malignancies present an intrinsic complexity in the initial diagnostic phase, as well as in treatment choice, often due to unavailability of practice guidelines and the lack of data, which significantly limit treatment options.

The systematic evaluation and definition of complex and uncommon thoracic tumors requires multidisciplinary team discussion in order to reach the correct diagnosis and offer the best treatment;therefore, the aim of this Special Issue is to collate significant recent results surrounding rare thoracic tumors.



Specialsue





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine* (*miscellaneous*))

Contact Us

Biomedicines Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/biomedicines biomedicines@mdpi.com X@Biomed_MDPI